Research on Acute Stroke Treatments
The treatment of acute stroke is a very recent, rapidly evolving area of research. The Vanderbilt Stroke Center has been involved in research on the clot-dissolving drug, tissue-type thromboplastin activator (tPA) since 1992. Since 1996, intravenous tPA has been an approved treatment for acute, ischemic stroke. Vanderbilt Medical Center has an active stroke team, involved in screening and treatment of patients within the three-hour time window after onset of stroke symptoms. For selected patients up to six hours after onset, tPA can be given through an arterial catheter near the site of clot in a brain artery. This investigational therapy is offered in conjunction with Interventional Neuroradiology. The Vanderbilt Stroke Center has also participated in several trials of "neuroprotective" agents designed to reduce the development of brain damage after acute stroke.
Please also visit Dr. McLaughlin's URL to learn more about basic research in stroke.
If you are interested in applying for a faculty position in the stroke division, please visit: http://www.mc.vanderbilt.edu/neurology/strokeposition.htm.
Research in Stroke Prevention
These two studies are currently enrolling:
ARCADIA - Atrial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke
CREST-2 – Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial
For further information about stroke studies, please contact:
Please also visit http://www.vanderbiltstrokecenter.com for more information on stroke.